N-DEAVOUR®, produced by N-ovative Health Technologies (NHT), is Pakistan’s first Drug Eluting Coronary Stent System which prevents the recurrence of late stent restinosis. The drug in the mechanism is released in a controlled manner over time to not only save the coronary artery from future blockade, which is the mechanical function of a stent, but also from unhealthy cell growth as a response, which has been experienced widely by patients who implant a Bare Metal Stent.
Key Features
-
Everolimus Eluting Stent
-
Low lesion entry profile
-
Hydrophilic coated distal shaft
-
Superior trackability
-
Excellent biocompatibility
-
Optimum durability
-
Durable polymer coating technology
-
Low In-Stent Restenosis (ISR) Rate
-
Optimal healing
-
Efficient re-endothelialisation
Technical Details
N-DEAVOUR® is a combination product comprised of two key components: the stent (which includes a base coat of Poly Butyl Methacrylate (PBMA) and a top coat of PVDF-HFP (non-erodable polymer) and the active pharmaceutical ingredient Everolimus.
N-DEAVOUR® has an MP35NLT Cobalt-Chromium (major elements include Cobalt, Nickel, and Chromium) stent platform and is pre-mounted on a PTCA Balloon Dilatation Catheter
Everolimus is the active pharmaceutical ingredient in the N-DEAVOUR® stent. It is a semisynthetic macrolide immunosuppressant, synthesised by chemical modification of rapamycin (sirolimus). Drug content is 100µg/cm² Everolimus per/mm². The drug load is 100 μg/cm2 for all product sizes. The drug load is 100 μg/cm2 for all product sizes.
N-DEAVOUR® stent contains inactive ingredients including Poly N-Butyl Methacrylate (PBMA), a polymer that adheres to the stent and drug coating, and PVDF-HFP, which is comprised of vinylidene fluoride and hexafluoropropylene monomers as the drug matrix layer containing Everolimus.
PBMA is a homopolymer with a molecular weight (Mw) of 264,000 to 376,000 dalton. PVDF-HFP is a non-erodible semi-crystalline random copolymer with a molecular weight (Mw) of 254,000 to 293,000 dalton. The drug matrix copolymer is mixed with Everolimus (83%/17% w/w polymer/Everolimus ratio) and applied to the entire PBMA coated stent surface.
